Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Aldeyra Therapeutics, Inc. is a biotechnology company focused on discovering and developing novel therapies for immune-mediated and metabolic diseases. Its core technology centers on reactive aldehyde species (RASP) modulators, designed to regulate multiple inflammatory pathways simultaneously with reduced toxicity. Key product candidates include reproxalap for ocular inflammatory diseases and ADX-2191 for retinal disorders. Aldeyra targets large patient populations through pharmaceutical development and strategic partnerships for commercialization.
This description was generated via AI from an annual report. Updated about 1 year ago.